Harry S. Palmin is the COO & CFO at Acer Therapeutics Inc.
As the COO & CFO of Acer Therapeutics Inc, the total compensation of Mr Palmin at Acer Therapeutics Inc is $535,360. There are 1 executives at Acer Therapeutics Inc getting paid more, with Christopher Schelling having the highest compensation of $675,800.
Mr Palmin is 51, he's been the COO & CFO of Acer Therapeutics Inc since . There are 2 older and 3 younger executives at Acer Therapeutics Inc. The oldest executive at Acer Therapeutics Inc is Donald R. Joseph J.D., 67, who is the Chief Legal Officer & Sec..
Harry's mailing address filed with the SEC is 222 Third St #2240, Cambridge, MA 02142, USA.
Over the last 7 years, insiders at Acer Therapeutics Inc have traded over $0 worth of Acer Therapeutics Inc stock and bought 2,078,411 units worth $11,295,691 . The most active insiders traders include Steve Aselage, Chris Schelling a Life Science Ventures Vi Gm.... On average, Acer Therapeutics Inc executives and independent directors trade stock every 165 days with the average trade being worth of $170,051. The most recent stock trade was executed by Chris Schelling on 29 November 2022, trading 819,672 units of ACER stock currently worth $1,000,000.
acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica
Acer Therapeutics Inc executives and other stock owners filed with the SEC include: